Harrow Inc (HROW) - Tuesday, Oct 31, 2023
Harrow owns commercial rights to ten branded ophthalmic pharmaceutical products and operates ImprimisRx, a pharmaceutical-compounding business.
Santen Pharmaceutical (4536 JP): Aims to Ride Patent Cliff Through Focus on Improving Profitability
Despite mainstay products losing patent protection, Santen targets core operating profit margin of 20% in FY26 (from 16% in FY23) through...
No more insights